Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Update

Dominari Holdings Inc. (NASDAQ:DOMH) was the target of a significant drop in short interest in the month of May. As of May 29th, there was short interest totaling 349,871 shares, a drop of 33.7% from the May 14th total of 527,421 shares. Approximately 3.5% of the company’s shares are sold short. Based on an average trading volume of 141,717 shares, the days-to-cover ratio is presently 2.5 days.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Dominari from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Dominari Stock Performance

Shares of DOMH opened at $3.26 on Tuesday. The company has a 50 day moving average price of $3.17 and a 200-day moving average price of $3.60. Dominari has a fifty-two week low of $2.68 and a fifty-two week high of $8.40. The stock has a market capitalization of $73.71 million, a PE ratio of -0.81 and a beta of 0.80.

Dominari (NASDAQ:DOMH) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($2.11) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($1.94). Dominari had a negative return on equity of 206.20% and a negative net margin of 31.37%.The business had revenue of $35.81 million during the quarter, compared to analysts’ expectations of $35.81 million.

Dominari Announces Dividend

The firm also recently declared a special dividend, which was paid on Friday, May 29th. Stockholders of record on Friday, May 15th were given a $0.31 dividend. The ex-dividend date of this dividend was Friday, May 15th.

Institutional Investors Weigh In On Dominari

Several hedge funds have recently modified their holdings of DOMH. PFG Investments LLC lifted its position in shares of Dominari by 36.3% in the 1st quarter. PFG Investments LLC now owns 14,475 shares of the company’s stock worth $47,000 after purchasing an additional 3,855 shares during the period. NewEdge Advisors LLC purchased a new stake in Dominari during the fourth quarter valued at approximately $50,000. Price T Rowe Associates Inc. MD purchased a new stake in Dominari during the fourth quarter valued at approximately $96,000. Oxford Asset Management LLP purchased a new stake in Dominari during the fourth quarter valued at approximately $120,000. Finally, Jane Street Group LLC purchased a new stake in Dominari during the second quarter valued at approximately $158,000. Hedge funds and other institutional investors own 42.48% of the company’s stock.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.